Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

abstract：:Aminoglycoside antibiotics are very important in the treatment of Gram-negative infections and as synergistic agents for the treatment of staphylococcal and streptococcal (group B streptococci and enterococci) infections. However, these agents have a narrow therapeutic index. Thus, a number of new antibiotics have bee...

journal_title：Clinical pharmacokinetics

authors： Bertino JS Jr,Rodvold KA,Destache CJ

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND AND AIMS:In this study, we evaluate the performance of allometric concepts to predict the implications of age and size on the pharmacokinetics of lamotrigine, and assess the dose rationale across different age groups from 0.2 to 91 years. METHODS:An allometrically scaled pharmacokinetic model was developed ...

journal_title：Clinical pharmacokinetics

authors： van Dijkman SC,de Jager NCB,Rauwé WM,Danhof M,Della Pasqua O

更新日期：2018-08-01 00:00:00

abstract：:5-Fluorouracil, first introduced as a rationally synthesized anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the colon, breast and skin. This drug, an analogue of the naturally occurring pyrimidine uracil, is metabolised via the same metab...

journal_title：Clinical pharmacokinetics

authors： Diasio RB,Harris BE

更新日期：1989-04-01 00:00:00

abstract：:The ability of a wide variety of anionic, cationic, and neutral drugs to bind in a reversible manner to plasma proteins has long been recognised. Non-steroidal anti-inflammatory drugs (NSAIDs) are distinguished as a class by the high degree to which they bind to plasma protein. Plasma protein binding properties are pr...

journal_title：Clinical pharmacokinetics

authors： Lin JH,Cocchetto DM,Duggan DE

更新日期：1987-06-01 00:00:00

abstract：:Serum concentration measurements of antibacterial agents are increasingly used to optimise drug dosage regimens. However, this approach is only justified for drugs with a low therapeutic index and poor predictability of serum concentrations, such as the aminoglycosides, chloramphenicol and vancomycin, whereas the peni...

journal_title：Clinical pharmacokinetics

authors： Wenk M,Vozeh S,Follath F

更新日期：1984-11-01 00:00:00

abstract：:The ability of a new multiple-dose non-linear regression analysis program to predict steady-state aminoglycoside peak and trough serum concentrations was evaluated. 30 patients receiving either amikacin (7), gentamicin (10) or tobramycin (13) were studied. A standard method of prediction which requires the collection ...

journal_title：Clinical pharmacokinetics

authors： Koup JR,Killen T,Bauer LA

更新日期：1983-09-01 00:00:00

abstract：:With the aging population and its rapidly increasing prevalence, dementia has become an important public health concern in developed and developing countries. To date, the pharmacological treatment is symptomatic and based on the observed neurotransmitter disturbances. The four most commonly used drugs are donepezil, ...

journal_title：Clinical pharmacokinetics

authors： Noetzli M,Eap CB

更新日期：2013-04-01 00:00:00

abstract：:The pharmacokinetics of metoprolol have been studied in a group of patients with varying degrees of renal impairment and in healthy subjects after administration of 20 mg of metoprolol tartrate intravenously and 50 mg orally in a single dose and during steady-state conditions. There were no significant differences in ...

journal_title：Clinical pharmacokinetics

authors： Jordö L,Attman PO,Aurell M,Johansson L,Johnsson G,Regårdh CG

更新日期：1980-03-01 00:00:00

abstract：:Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate ...

journal_title：Clinical pharmacokinetics

authors： Zandvliet AS,Schellens JH,Beijnen JH,Huitema AD

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:To assess the differences between patients with hepatic insufficiency and healthy subjects with regard to the pharmacokinetics, cardiac safety and overall safety of ebastine and its active metabolite carebastine. DESIGN:Open-label parallel-group study. PARTICIPANTS:24 patients with varying degrees of hepati...

journal_title：Clinical pharmacokinetics

authors： Lasseter KC,Dilzer SC,Vargas R,Waldman S,Noveck RJ

更新日期：2004-01-01 00:00:00

abstract：:Ketoprofen, a potent nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class, has been used clinically for over 15 years in Europe, and has recently been introduced in the United States. Although it possesses a chiral centre, with only the S-enantiomer possessing beneficial pharmacological activi...

journal_title：Clinical pharmacokinetics

authors： Jamali F,Brocks DR

更新日期：1990-09-01 00:00:00

abstract：:In the past decade, fludarabine has had a major impact in increasing the effectiveness of treatment of patients with indolent B-cell malignancies. This has come about in a variety of clinical circumstances, including use of fludarabine alone as well as in combinations with DNA-damaging agents or membrane-targeted anti...

journal_title：Clinical pharmacokinetics

authors： Gandhi V,Plunkett W

更新日期：2002-01-01 00:00:00

abstract：:Pharmacological treatment of patients with Alzheimer's disease is becoming more important, as evidenced by the number of drugs being developed in different countries. It has been shown in the majority of clinical trials that cholinesterase inhibitors, such as tacrine (tetrahydroaminoacridine), are able to induce benef...

journal_title：Clinical pharmacokinetics

authors： Parnetti L

更新日期：1995-08-01 00:00:00

abstract：:Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (...

journal_title：Clinical pharmacokinetics

authors： Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

更新日期：2017-11-01 00:00:00

abstract：:It should be recognized that children are not small adults, hence dosing in children should not be a 'small adult dose'. A mean population dose in all age groups is just an average dose and not necessarily the best or the correct dose for a given patient. The dose of a drug varies from patient to patient and individua...

journal_title：Clinical pharmacokinetics

authors： Mahmood I

更新日期：2014-04-01 00:00:00

abstract：:Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. It is used in the treatment of glaucoma to lower the intraocular pressure. After absorption via the cornea and stroma, it inhibits carbonic anhydrase in the ciliary process, which leads to a reduction of aqueous humour production and the...

journal_title：Clinical pharmacokinetics

authors： Martens-Lobenhoffer J,Banditt P

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

journal_title：Clinical pharmacokinetics

authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

更新日期：2010-06-01 00:00:00

abstract：:All of the commonly used anticonvulsants drugs, except possibly primidone, are cleared from the human body mainly by metabolism. The metabolites of phenytoin, phenobarbital and ethosuximide have so far not been shown to possess significant pharmacological activity. However, carbamazepine-10,11-epoxide, derived from ca...

journal_title：Clinical pharmacokinetics

authors： Eadie MJ

更新日期：1991-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson's disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa-carbidopa intestinal gel (LCIG) provides individualized continuous levodopa-carbidopa delivery through in...

journal_title：Clinical pharmacokinetics

authors： Othman AA,Chatamra K,Mohamed ME,Dutta S,Benesh J,Yanagawa M,Nagai M

更新日期：2015-09-01 00:00:00

abstract：OBJECTIVE:To explore the ability of the nonparametric expectation maximisation (NPEM) method of population pharmacokinetic modelling to deal with sparse data in estimating systemic caffeine clearance for monitoring and evaluation of cytochrome P450 (CYP) 1A2 activity. DESIGN AND PARTICIPANTS:Nonblind, single-dose clin...

journal_title：Clinical pharmacokinetics

authors： Terziivanov D,Bozhinova K,Dimitrova V,Atanasova I

更新日期：2003-01-01 00:00:00

abstract：:Uncertainty exists as to the most suitable pharmacokinetic parameter sets for propofol target-controlled infusions (TCI). The pharmacokinetic parameter sets currently employed are clearly not universally applicable, particularly when patient attributes differ from those of the subjects who participated in the original...

journal_title：Clinical pharmacokinetics

authors： Coetzee JF

更新日期：2012-03-01 00:00:00

abstract：:In the treatment of patients with Parkinson's disease, apomorphine has an established place as a back-up therapy if other antiparkinsonian drugs, such as levodopa and oral dopamine agonists, have not controlled the existing response fluctuations. Apomorphine is a synthetic derivative of morphine, with a totally distin...

journal_title：Clinical pharmacokinetics

authors： Neef C,van Laar T

更新日期：1999-09-01 00:00:00

abstract：:This review examines the literature on drug interactions with omeprazole. Different mechanisms have been proposed as potential causes for such interactions. First, the absorption of some drugs might be altered due to the decreased intragastric acidity resulting from omeprazole treatment. There was no effect of omepraz...

journal_title：Clinical pharmacokinetics

authors： Andersson T

更新日期：1991-09-01 00:00:00

abstract：:Pharmacokinetic parameters of third generation cephalosporins vary widely, requiring different dosage regimens and adjustment methods for each agent. Although their antibacterial spectrum favours their usage in infections caused by aerobic Gram-negative organisms, due to their limited post-antibiotic effect against th...

journal_title：Clinical pharmacokinetics

authors： Yuk-Choi JH,Nightingale CH,Williams TW Jr

更新日期：1992-02-01 00:00:00

abstract：:Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of...

journal_title：Clinical pharmacokinetics

authors： Michalets EL,Williams CR

更新日期：2000-07-01 00:00:00

abstract：:Recent international guidelines on the detection, clinical assessment and management of patients with hypertension have highlighted a number of themes that should be incorporated into routine clinical practice. First, although antihypertensive therapy is having a major impact on reducing the incidence of coronary hear...

journal_title：Clinical pharmacokinetics

authors： Donnelly R

更新日期：1999-01-01 00:00:00

abstract：:Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level. The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone. The pharmacokinetics of mifepristone are characterised by rapid absorption, a ...

journal_title：Clinical pharmacokinetics

authors： Heikinheimo O

更新日期：1997-07-01 00:00:00

abstract：:Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of multiple sclerosis (MS) and is also used in chronic lymphocytic leukemia (CLL). Alemtuzumab is used off-label in kidney transplantation as ind...

journal_title：Clinical pharmacokinetics

authors： van der Zwan M,Baan CC,van Gelder T,Hesselink DA

更新日期：2018-02-01 00:00:00

abstract：OBJECTIVE:To assess the dose proportionality of lacidipine after single and repeated oral doses, and to obtain new information on the pharmacokinetics of the compound since improvement of the plasma assay method. DESIGN:Open, randomised, four-way cross-over trial. PARTICIPANTS:24 healthy male and female volunteers, a...

journal_title：Clinical pharmacokinetics

authors： Da Ros L,Squassante L,Milleri S

更新日期：2003-01-01 00:00:00

abstract：:A reduction in plasma albumin concentration, as seen in patients with the nephrotic syndrome, is usually associated with a decrease in plasma protein binding of highly bound drugs. Therefore, the fraction of the unbound drug increases, but the absolute free concentration remains essentially unchanged due to a compensa...

journal_title：Clinical pharmacokinetics

authors： Gugler R,Azarnoff DL

更新日期：1976-01-01 00:00:00